Symbols / COCP Stock $1.43 +1.42% Cocrystal Pharma, Inc.

Healthcare • Biotechnology • United States • NCM
COCP (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Sam Lee Ph.D.
Exch · Country NCM · United States
Market Cap 19.71M
Enterprise Value 14.19M
Income -8.83M
Sales —
FCF (ttm) -4.95M
Book/sh 0.46
Cash/sh 0.51
Employees 10
Insider 10d —
IPO Feb 22, 2012
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -2.23
PEG —
P/S —
P/B 3.12
P/C —
EV/EBITDA -1.59
EV/Sales —
Quick Ratio 3.50
Current Ratio 3.68
Debt/Eq 23.77
LT Debt/Eq —
EPS (ttm) -0.78
EPS next Y -0.64
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-03-31
Earnings (prior) 2026-03-31
ROA -48.66%
ROE -111.40%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 13.79M
Shs Float 9.12M
Insider Own 25.45%
Instit Own 5.57%
Short Float 11.68%
Short Ratio 0.15
Short Interest 988.35K
52W High 2.67
vs 52W High -46.44%
52W Low 0.86
vs 52W Low 66.28%
Beta 1.18
Impl. Vol. —
Rel Volume 0.06
Avg Volume 2.42M
Volume 141.34K
Target (mean) $8.00
Tgt Median $8.00
Tgt Low $6.00
Tgt High $10.00
# Analysts 3
Recom None
Prev Close $1.41
Price $1.43
Change 1.42%
About

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. It employs structure-based technologies to create antiviral drugs including influenza virus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as norovirus, respiratory virus infections, and hepatitis C virus (HCV) infections. The company develops CC-42344, a novel PB2 inhibitor, which is in phase 2a clinical trial, as a potential treatment for pandemic and seasonal influenza A; and the inhaled CC-42344 for the potential prophylactic treatment of pandemic and seasonal influenza infections. It is also developing CDI-988, an oral pan-viral, which is phase 1 clinical trial to treat noroviruses and coronaviruses, including SARS-CoV-2 and its variants; and CC-31244, a HCV non-nucleoside inhibitor that has completed Phase 2a clinical trial to treat HCV. The company has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. Cocrystal Pharma, Inc. was founded in 2006 and is based in Bothell, Washington.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$8.00
Mean price target
2. Current target
$1.43
Latest analyst target
3. DCF / Fair value
$-6.46
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.43
Low
$6.00
High
$10.00
Mean
$8.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-06-20 main HC Wainwright & Co. Buy → Buy $6
2025-01-22 reit HC Wainwright & Co. Buy → Buy $7
2024-05-14 reit HC Wainwright & Co. Buy → Buy $10
2024-04-04 reit HC Wainwright & Co. Buy → Buy $10
2024-03-20 reit HC Wainwright & Co. Buy → Buy $10
2024-01-03 main HC Wainwright & Co. Buy → Buy $10
2023-12-04 reit HC Wainwright & Co. Buy → Buy $12
2023-10-04 reit HC Wainwright & Co. Buy → Buy $12
2023-08-15 reit HC Wainwright & Co. Buy → Buy $12
2023-08-11 reit HC Wainwright & Co. Buy → Buy $12
2023-06-02 reit HC Wainwright & Co. Buy → Buy $12
2023-05-24 main HC Wainwright & Co. Buy → Buy $12
2023-01-24 main HC Wainwright & Co. — → Buy $35
2022-11-07 main HC Wainwright & Co. — → Buy $42
News
RSS: Latest COCP news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-02-24 FROST PHILLIP MD ET AL Director and Beneficial Owner of more than 10% of a Class of Security — 20,000 $1.00 $19,952
2026-02-06 FROST PHILLIP MD ET AL Beneficial Owner of more than 10% of a Class of Security — 50,000 $0.95 $47,280
2025-12-31 FROST PHILLIP MD ET AL Beneficial Owner of more than 10% of a Class of Security — 50,000 $0.95 $47,275
2025-12-30 FROST PHILLIP MD ET AL Beneficial Owner of more than 10% of a Class of Security — 20,000 $0.97 $19,310
2025-12-26 FROST PHILLIP MD ET AL Beneficial Owner of more than 10% of a Class of Security — 65,000 $0.97 $63,202
2025-11-26 FROST PHILLIP MD ET AL Beneficial Owner of more than 10% of a Class of Security — 4,000 $0.99 $3,975
2025-11-25 FROST PHILLIP MD ET AL Beneficial Owner of more than 10% of a Class of Security — 20,000 $0.94 $18,812
2025-10-28 PFENNIGER RICHARD C JR Director — 20,000 $0.00 $0
2025-10-28 MARTIN JAMES J. CPA Chief Executive Officer — 3,598 $1.15 $4,138
2025-10-28 FROST PHILLIP MD ET AL Beneficial Owner of more than 10% of a Class of Security — 359,713 $1.15 $413,670
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
9.02
-49.55%
17.88
-15.51%
21.16
+16.66%
18.14
Research And Development
5.05
-59.68%
12.54
-17.35%
15.17
+22.41%
12.39
Selling General And Administration
3.96
-25.78%
5.34
-10.83%
5.99
+4.26%
5.75
General And Administrative Expense
3.96
-25.78%
5.34
-10.83%
5.99
+4.26%
5.75
Other Gand A
3.96
-25.78%
5.34
-10.83%
5.99
+4.26%
5.75
Total Expenses
9.02
-49.55%
17.88
-15.51%
21.16
+16.66%
18.14
Operating Income
-9.02
+49.55%
-17.88
+15.51%
-21.16
-16.66%
-18.14
Total Operating Income As Reported
-9.02
+49.55%
-17.88
+3.67%
-18.56
+52.20%
-38.83
EBITDA
-8.64
+50.42%
-17.43
+17.61%
-21.16
-19.21%
-17.75
Normalized EBITDA
-8.70
+49.64%
-17.27
+27.12%
-23.69
-903.46%
2.95
Reconciled Depreciation
0.38
-15.70%
0.45
+132.13%
-1.39
-457.73%
0.39
EBIT
-9.02
+49.55%
-17.88
+15.51%
-21.16
-16.66%
-18.14
Total Unusual Items
0.05
+133.13%
-0.16
-106.43%
2.54
+112.25%
-20.70
Total Unusual Items Excluding Goodwill
0.05
+133.13%
-0.16
-106.43%
2.54
+112.25%
-20.70
Special Income Charges
—
0.00
-100.00%
2.60
+112.57%
-20.69
Other Special Charges
—
—
-2.60
-262.50%
1.60
Impairment Of Capital Assets
—
—
0.00
-100.00%
19.09
Net Income
-8.83
+49.55%
-17.50
+2.67%
-17.98
+53.69%
-38.84
Pretax Income
-8.83
+49.55%
-17.50
+2.67%
-17.98
+53.69%
-38.84
Net Non Operating Interest Income Expense
0.13
-75.05%
0.54
-16.09%
0.64
+32100.00%
-0.00
Interest Expense Non Operating
—
—
—
0.00
Net Interest Income
0.13
-75.05%
0.54
-16.09%
0.64
+32100.00%
-0.00
Interest Expense
—
—
—
0.00
Other Income Expense
0.05
+133.13%
-0.16
-106.43%
2.54
+112.25%
-20.70
Gain On Sale Of Security
0.05
+133.13%
-0.16
-150.77%
-0.07
-983.33%
-0.01
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-8.83
+49.55%
-17.50
+2.67%
-17.98
+53.69%
-38.84
Net Income From Continuing Operation Net Minority Interest
-8.83
+49.55%
-17.50
+2.67%
-17.98
+53.69%
-38.84
Net Income From Continuing And Discontinued Operation
-8.83
+49.55%
-17.50
+2.67%
-17.98
+53.69%
-38.84
Net Income Continuous Operations
-8.83
+49.55%
-17.50
+2.67%
-17.98
+53.69%
-38.84
Normalized Income
-8.88
+48.76%
-17.34
+15.49%
-20.52
-13.12%
-18.14
Net Income Common Stockholders
-8.83
+49.55%
-17.50
+2.67%
-17.98
+53.69%
-38.84
Diluted EPS
-0.78
+54.65%
-1.72
+8.02%
-1.87
+60.80%
-4.77
Basic EPS
-0.78
+54.65%
-1.72
+8.02%
-1.87
+60.80%
-4.77
Basic Average Shares
11.29
+10.97%
10.17
+5.42%
9.65
+18.52%
8.14
Diluted Average Shares
11.29
+10.97%
10.17
+5.42%
9.65
+18.52%
8.14
Diluted NI Availto Com Stockholders
-8.83
+49.55%
-17.50
+2.67%
-17.98
+53.69%
-38.84
Total Other Finance Cost
-0.13
+75.05%
-0.54
+16.09%
-0.64
-32100.00%
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
9.71
-27.82%
13.46
-56.95%
31.26
-23.46%
40.84
Current Assets
8.13
-29.76%
11.58
-60.19%
29.09
-27.59%
40.18
Cash Cash Equivalents And Short Term Investments
7.03
-28.75%
9.86
-62.58%
26.35
-29.05%
37.14
Cash And Cash Equivalents
7.03
-28.75%
9.86
-62.58%
26.35
-29.05%
37.14
Cash Financial
7.03
-28.75%
9.86
-62.58%
26.35
-29.05%
37.14
Receivables
0.71
-41.89%
1.22
+36.52%
0.89
+24.30%
0.72
Accounts Receivable
—
—
—
—
Taxes Receivable
0.71
-41.89%
1.22
+36.52%
0.89
+24.30%
0.72
Prepaid Assets
—
—
—
—
Restricted Cash
0.07
+0.00%
0.07
+0.00%
0.07
+0.00%
0.07
Other Current Assets
0.33
-23.72%
0.43
-75.75%
1.77
-20.95%
2.24
Total Non Current Assets
1.58
-15.88%
1.88
-13.47%
2.17
+227.49%
0.66
Net PPE
1.48
-19.71%
1.85
-12.96%
2.12
+244.48%
0.62
Gross PPE
3.48
-7.73%
3.78
-3.80%
3.92
+76.01%
2.23
Accumulated Depreciation
-2.00
-3.73%
-1.93
-6.99%
-1.80
-11.71%
-1.61
Machinery Furniture Equipment
0.15
+0.00%
0.15
+0.00%
0.15
+18.32%
0.13
Other Properties
3.33
-8.06%
3.62
-3.95%
3.77
+79.61%
2.10
Goodwill And Other Intangible Assets
—
—
—
0.00
Goodwill
—
—
—
0.00
Non Current Prepaid Assets
0.10
+227.59%
0.03
-36.96%
0.05
+0.00%
0.05
Total Liabilities Net Minority Interest
3.38
-14.04%
3.93
-19.32%
4.88
+282.95%
1.27
Current Liabilities
2.21
-8.98%
2.43
-25.57%
3.26
+168.26%
1.22
Payables And Accrued Expenses
1.79
-10.90%
2.01
-31.00%
2.91
+244.33%
0.85
Payables
0.89
-42.28%
1.54
+26.19%
1.22
+99.02%
0.61
Accounts Payable
0.89
-42.28%
1.54
+26.19%
1.22
+99.02%
0.61
Current Accrued Expenses
0.90
+92.52%
0.47
-72.32%
1.69
+628.88%
0.23
Pensionand Other Post Retirement Benefit Plans Current
0.09
-27.35%
0.12
+7.34%
0.11
-16.15%
0.13
Current Debt And Capital Lease Obligation
0.33
+10.96%
0.30
+25.42%
0.24
+0.00%
0.24
Current Capital Lease Obligation
0.33
+10.96%
0.30
+25.42%
0.24
+0.00%
0.24
Other Current Liabilities
—
—
—
—
Total Non Current Liabilities Net Minority Interest
1.17
-22.19%
1.50
-6.70%
1.61
+2729.82%
0.06
Long Term Debt And Capital Lease Obligation
1.17
-22.19%
1.50
-6.70%
1.61
+2729.82%
0.06
Long Term Capital Lease Obligation
1.17
-22.19%
1.50
-6.70%
1.61
+2729.82%
0.06
Stockholders Equity
6.33
-33.52%
9.52
-63.91%
26.38
-33.32%
39.57
Common Stock Equity
6.33
-33.52%
9.52
-63.91%
26.38
-33.32%
39.57
Capital Stock
0.01
+30.00%
0.01
+0.00%
0.01
+25.00%
0.01
Common Stock
0.01
+30.00%
0.01
+0.00%
0.01
+25.00%
0.01
Share Issued
13.78
+35.49%
10.17
+0.00%
10.17
+24.94%
8.14
Ordinary Shares Number
13.78
+35.49%
10.17
+0.00%
10.17
+24.94%
8.14
Additional Paid In Capital
348.57
+1.64%
342.93
+0.19%
342.29
+1.42%
337.49
Retained Earnings
-342.25
-2.65%
-333.42
-5.54%
-315.91
-6.04%
-297.93
Total Equity Gross Minority Interest
6.33
-33.52%
9.52
-63.91%
26.38
-33.32%
39.57
Total Capitalization
6.33
-33.52%
9.52
-63.91%
26.38
-33.32%
39.57
Working Capital
5.92
-35.27%
9.15
-64.57%
25.83
-33.71%
38.96
Invested Capital
6.33
-33.52%
9.52
-63.91%
26.38
-33.32%
39.57
Total Debt
1.50
-16.67%
1.81
-2.54%
1.85
+523.91%
0.30
Capital Lease Obligations
1.50
-16.67%
1.81
-2.54%
1.85
+523.91%
0.30
Net Tangible Assets
6.33
-33.52%
9.52
-63.91%
26.38
-33.32%
39.57
Tangible Book Value
6.33
-33.52%
9.52
-63.91%
26.38
-33.32%
39.57
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-8.19
+50.31%
-16.48
-12.40%
-14.67
+31.58%
-21.43
Cash Flow From Continuing Operating Activities
-8.19
+50.31%
-16.48
-12.40%
-14.67
+31.58%
-21.43
Net Income From Continuing Operations
-8.83
+49.55%
-17.50
+2.67%
-17.98
+53.69%
-38.84
Depreciation Amortization Depletion
0.38
-15.70%
0.45
+132.13%
-1.39
-457.73%
0.39
Depreciation
0.38
-15.70%
0.45
+132.13%
-1.39
-457.73%
0.39
Depreciation And Amortization
0.38
-15.70%
0.45
+132.13%
-1.39
-457.73%
0.39
Other Non Cash Items
-0.30
-43.33%
-0.21
-113.44%
1.56
+847.85%
-0.21
Stock Based Compensation
0.27
-58.01%
0.64
-19.73%
0.80
-6.32%
0.85
Asset Impairment Charge
—
—
0.00
-100.00%
19.09
Operating Gains Losses
—
—
—
-0.01
Gain Loss On Investment Securities
—
—
—
-0.01
Change In Working Capital
0.29
+110.00%
0.14
-94.02%
2.34
+186.36%
-2.71
Change In Receivables
0.51
+256.62%
-0.33
-86.78%
-0.17
+75.70%
-0.72
Changes In Account Receivables
—
—
—
0.00
Change In Prepaid Assets
0.04
-97.35%
1.36
+189.36%
0.47
+128.06%
-1.68
Change In Payables And Accrued Expense
-0.25
+71.96%
-0.90
-143.74%
2.05
+737.38%
-0.32
Change In Other Current Assets
—
—
—
—
Investing Cash Flow
-0.01
-50.00%
-0.01
+93.22%
-0.12
-59.46%
-0.07
Cash Flow From Continuing Investing Activities
-0.01
-50.00%
-0.01
+93.22%
-0.12
-59.46%
-0.07
Net PPE Purchase And Sale
-0.01
-50.00%
-0.01
+93.22%
-0.12
-59.46%
-0.07
Purchase Of PPE
-0.01
-50.00%
-0.01
+93.22%
-0.12
-59.46%
-0.07
Capital Expenditure
-0.01
-50.00%
-0.01
+93.22%
-0.12
-59.46%
-0.07
Financing Cash Flow
5.37
0.00
-100.00%
3.99
+14888.89%
-0.03
Cash Flow From Continuing Financing Activities
5.37
0.00
-100.00%
3.99
+14888.89%
-0.03
Net Issuance Payments Of Debt
—
0.00
+100.00%
-0.01
+74.07%
-0.03
Repayment Of Debt
—
0.00
+100.00%
-0.01
+74.07%
-0.03
Long Term Debt Payments
—
0.00
+100.00%
-0.01
+74.07%
-0.03
Net Long Term Debt Issuance
—
0.00
+100.00%
-0.01
+74.07%
-0.03
Net Common Stock Issuance
5.37
0.00
-100.00%
4.00
0.00
Changes In Cash
-2.83
+82.81%
-16.49
-52.84%
-10.79
+49.89%
-21.54
Beginning Cash Position
9.94
-62.41%
26.43
-28.99%
37.22
-36.65%
58.76
End Cash Position
7.10
-28.54%
9.94
-62.41%
26.43
-28.99%
37.22
Free Cash Flow
-8.20
+50.26%
-16.49
-11.56%
-14.78
+31.27%
-21.51
Common Stock Issuance
5.37
0.00
-100.00%
4.00
0.00
Issuance Of Capital Stock
5.37
0.00
-100.00%
4.00
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category